Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 328

Unit DX marks $25.5m in portfolio funding

Members of science incubator Unit DX have obtained $25.5m of capital altogether since launch in 2017, with many of its residents hailing from University of Bristol.

May 21, 2019

Google places LowRisc bet

Cambridge open source hardware spinout LowRisc has been backed by Alphabet's Google, which has sent two representatives to its board of directors.

May 21, 2019

Rinri rings in $1.8m seed round

Sheffield cell therapy spinout Rinri secured corporate backing from Boehringer Ingelheim and UCB in a seed round that will drive work on stem cell-based treatments for hearing loss.

May 21, 2019

Prowler.io pounces on $24m

CIC has returned to supply AI forecasting platform Prowler.io with series B capital and help take the company's overall funding to $39m.

May 21, 2019

GetYourGuide goes to $484m series E

ETH Zurich spinout GetYourGuide secured $484m in a round led by SoftBank Vision Fund that took its total funding past $650m.

May 21, 2019

Prowler.io pounces on $24m

Pearson, Tencent and Mandatum Life helped supply the AI forecasting platform developer with series B capital that took its total funding to $39m.

May 21, 2019

Storm attracts more series A funding

M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.

May 20, 2019

UCEF IV binds to PolyProx

The Parkwalk-managed co-investment fund has supplied Cambridge cancer therapy spinout PolyProx Therapeutics with capital, augmenting a $4.4m seed round for the latter announced earlier this month.

May 20, 2019

Big deal: Syncona composes Quell with $46m series A

Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.

May 20, 2019

Storm's series A continues to resound with investors

Cambridge's cancer drug spinout Storm Therapeutics convinced its existing investors to join new participant Seroba Life Sciences for a second extension that brought its series A total to $38.2m.

May 20, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here